 (IC)
increased mean pain-free walking time, maximum walking
time, Walking Impairment Questionnaire scores and the
Physical Component Summary score. The Society guideline
published earlier this year4 had considered evidence from
this trial and suggested the use of ramipril in patients with
IC (Recommendation 4.11). The recommendation was a
weak one (ie, suggestion) because the trial was small and
the results had not been replicated in other trials with a longer